Research programme: tuberculosis vaccines - Aeras/China National Biotec Group

Drug Profile

Research programme: tuberculosis vaccines - Aeras/China National Biotec Group

Latest Information Update: 04 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aeras Global TB Vaccine Foundation; China National Biotec Group
  • Developer Aeras; China National Biotec Group
  • Class Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Tuberculosis

Most Recent Events

  • 29 Aug 2013 Aeras receives 5-year grant from Department for International Development in the United Kingdom for vaccine development in tuberculosis
  • 02 Oct 2012 Aeras Global TB Vaccine Foundation is now called Aeras
  • 10 Jan 2012 Aeras and CNBG reach final agreement to jointly develop TB vaccines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top